XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Operating activities:    
Net loss $ (106,769,000) $ (113,234,000)
Adjustments to reconcile net loss to net cash used for operating activities:    
Stock-based compensation expense 23,088,000 30,608,000
Depreciation and amortization 1,366,000 959,000
Amortization of debt discount 645,000 507,000
Realized gain on available-for-sale securities 0 (8,000)
Accretion of discount on short-term investments (82,000) (2,437,000)
Impairment of property and equipment 53,000 54,000
Loss on disposal of property and equipment   53,000
Change in operating assets and liabilities:    
Accounts receivable 2,377,000 (2,169,000)
Inventory (16,474,000) 9,762,000
Prepaid expenses and other assets 10,136,000 2,454,000
Accounts payable 15,700,000 (8,866,000)
Accrued clinical and manufacturing liabilities (4,441,000) 913,000
Accrued payroll and employee liabilities (4,055,000) (4,415,000)
Other accrued liabilities (11,756,000) 13,687,000
Net cash used for operating activities (90,212,000) (72,132,000)
Investing activities:    
Purchases of short-term investments (66,915,000) (204,358,000)
Maturities and sales of short-term investments 166,825,000 284,606,000
Purchases of property and equipment (3,687,000) (4,299,000)
Net cash provided by investing activities 96,223,000 75,949,000
Financing activities:    
Proceeds from stock option exercises 1,309,000 16,215,000
Proceeds from purchases under the Employee Stock Purchase Plan 1,507,000 1,170,000
Proceeds from warrant exercises 3,000  
Net cash provided by financing activities 2,819,000 17,385,000
Net increase in cash and cash equivalents 8,830,000 21,202,000
Cash and cash equivalents at beginning of year 71,898,000 31,836,000
Cash and cash equivalents at end of period $ 80,728,000 $ 53,038,000